ArticleEJIFCC2024
Validation of the KL6 Method on the G600II Analyser (Lumipulse) for Clinical Use in Interstitial Lung Disease.
Article in EJIFCC, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Clinical Laboratory (CL) is involved in the prevention, diagnosis and follow-up of disease, as well as in the monitoring of treatment. For this reason, the CL must have robust quality systems in place in order to provide reliable results that help to ensure correct health care. Since the entry into force of the European regulation (IVDR) on in vitro diagnostic medical devices (EU) 2017/746 has generated the loss of CE marking in some laboratory determinations. In our case, Krebs von den Lungen-6 (KL-6), a diagnostic, severity and prognostic marker, as well as a marker of response to treatment, currently has the RUO (research use only) marking and, given its importance in our healthcare environment, we have validated the method with the new reagent in order to be able to continue with the clinical care of patients. In addition, this would keep this analyte within the scope of accreditation. Following the specific CLSI protocols, we carried out a study of precision, linearity as well as the limit of blank and the limit of detection, obtaining results within the limits established by the laboratory. This positive validation of KL6 allows us to continue using this analyte for clinical use and within the scope of accreditation.
Indexed as
Identifiers
39810896PMC11726327What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.